1. Introduction {#sec1-microorganisms-07-00400}
===============

Three decades after their emergence in Europe \[[@B1-microorganisms-07-00400],[@B2-microorganisms-07-00400]\], vancomycin-resistant enterococci (VRE) were classified by the World Health Organization in 2017 as microorganisms with a high level of priority regarding the research and development of new and effective antibiotics \[[@B3-microorganisms-07-00400]\]. The increasing incidence of invasive infections caused by VRE represents a public health challenge in Germany \[[@B4-microorganisms-07-00400]\] as well as in several regions worldwide \[[@B5-microorganisms-07-00400]\]. Additionally, cross-genus horizontal gene transfer observed between VRE and methicillin-resistant *Staphylococcus aureus* (MRSA) represents a major concern as the transmission of *vanA* and *cfr* genes has been shown to render resistance against vancomycin and linezolid to MRSA strains \[[@B6-microorganisms-07-00400],[@B7-microorganisms-07-00400],[@B8-microorganisms-07-00400]\]. The risk for the spread of VRE is highest in the healthcare setting \[[@B9-microorganisms-07-00400]\], partially due to a high proportion of patients either being already colonized \[[@B10-microorganisms-07-00400],[@B11-microorganisms-07-00400]\] or displaying risk factors that favor this condition, e.g., comorbidities, immunosuppressive diseases, or steroid or antibiotic treatment \[[@B12-microorganisms-07-00400],[@B13-microorganisms-07-00400],[@B14-microorganisms-07-00400],[@B15-microorganisms-07-00400],[@B16-microorganisms-07-00400],[@B17-microorganisms-07-00400]\]. Several studies have demonstrated the relationship between the hospital-wide use of specific antimicrobials and the increasing incidence of nosocomial VRE transmission \[[@B15-microorganisms-07-00400],[@B18-microorganisms-07-00400],[@B19-microorganisms-07-00400]\]. The constant flux of VRE patients and healthcare workers through different areas of a healthcare facility \[[@B20-microorganisms-07-00400],[@B21-microorganisms-07-00400]\], as well as numerous surfaces and objects capable of acting as fomites also facilitate transmission in this setting \[[@B11-microorganisms-07-00400],[@B22-microorganisms-07-00400],[@B23-microorganisms-07-00400]\]. Strategies of infection control and prevention have been developed globally \[[@B24-microorganisms-07-00400]\], aiming at reducing the transmission of VRE. Although the gut is considered to be the main reservoir in humans, decolonization regimens are not feasible yet. Instead, bundles of measures that passively minimize the risk of transmission are adopted. Within the German healthcare system, these strategies focus on the detection of VRE carriers by screening for rectal colonization, the establishment of contact precautions, the disinfection of potentially contaminated surfaces and elements present in the environment, as well as the implementation of antibiotic stewardships programs as a preventive approach \[[@B25-microorganisms-07-00400],[@B26-microorganisms-07-00400]\]. Although such measures have proven to be effective in containing the spread of multiresistant microorganisms, they are cost and time intensive, requiring trained personnel and a high compliance for successful implementation \[[@B27-microorganisms-07-00400]\]. Contact precautions may be discontinued once the clearance of colonization with VRE has been documented, indicated by negative results on at least three consecutive occasions, greater than or equal to one week apart. This definition was established by the Centers for Disease Control and Prevention in 1995 \[[@B28-microorganisms-07-00400]\], and has since then been broadly adopted in infection control standards, including the national German guidelines on prevention of infections with multidrug-resistant enterococci \[[@B26-microorganisms-07-00400]\]. Since VRE colonization is generally thought to persist chronically in most patients, contact precautions are usually maintained over long periods \[[@B29-microorganisms-07-00400]\]. The detection of VRE clearance allows for the discontinuation of all infection control measures, therefore requiring a close assessment of the VRE status by performing periodical follow-up screenings. We hypothesize that the number of patients with spontaneous VRE clearance is currently underestimated as recommendations for regular assessment of colonization are generally lacking. We therefore elucidated, here, the real proportion of long-term VRE carriage and analyzed risk factors associated with long-term VRE carriage.

2. Materials and Methods {#sec2-microorganisms-07-00400}
========================

2.1. Clinical Setting and Infection Control Measures {#sec2dot1-microorganisms-07-00400}
----------------------------------------------------

The 1527-bed University Hospital Münster (UHM) is a tertiary care center, admitting ca. 65,000 patients every year. In the daily routine, screening for multidrug-resistant organisms is performed for methicillin-resistant *Staphylococcus aureus* (MRSA) and multidrug-resistant Gram-negative bacteria according to the national German guidelines \[[@B30-microorganisms-07-00400],[@B31-microorganisms-07-00400]\]. A standardized VRE screening is carried out in patients at high risk of developing VRE infections (i.e., hemato-oncological patients) or in patients with a history of VRE colonization and/or infection. This screening policy, established in the beginning of 2016, is in accordance with the national German guidelines published in October 2018 \[[@B26-microorganisms-07-00400]\]. In case of VRE detection (colonization/infection), extended hygiene measures include contact isolation of the VRE patient in a separate room with separate sanitary facilities. Staff members and visitors are advised to wear personal protective equipment consisting of gloves and gowns. Surface disinfection is performed at least once a day. Patient isolation can be stopped if three anorectal swabs, taken at least one week apart, are negative for VRE providing that patients are not under antibiotic treatment during this time.

2.2. Detection of VRE Long-Term Carriers {#sec2dot2-microorganisms-07-00400}
----------------------------------------

During a two-year period (October 2016--October 2018) VRE positive patients admitted to the UHM were recruited. Patients who were not readmitted after the initial VRE diagnosis were excluded, since the evolution of the VRE status could not be assessed in these cases. Swabs taken from these patients during the first hospital stay or after readmission were collected. In the absence of established definitions, patients were classified as "VRE long-term carriers" if rectal colonization with the same VRE genotype was still present ≥10 weeks after first VRE detection in rectal swabs \[[@B32-microorganisms-07-00400]\]. In parallel, risk factors known to favor VRE colonization \[[@B11-microorganisms-07-00400],[@B12-microorganisms-07-00400],[@B13-microorganisms-07-00400],[@B14-microorganisms-07-00400],[@B15-microorganisms-07-00400],[@B16-microorganisms-07-00400],[@B17-microorganisms-07-00400]\] were recorded. These included age, gender, overall length of stay, number of admissions, average length of stay per admission, number of stays, comorbidities, immunosuppressive diseases, steroid treatment, admission from another hospital or ICU, and antibiotic treatment, especially concentrating on frequently prescribed drugs known to select enterococci or VRE \[[@B12-microorganisms-07-00400],[@B13-microorganisms-07-00400],[@B15-microorganisms-07-00400],[@B33-microorganisms-07-00400],[@B34-microorganisms-07-00400]\].

2.3. VRE Swab Samples, Culturing, Antibiotic Susceptibility Testing, PCR Testing {#sec2dot3-microorganisms-07-00400}
--------------------------------------------------------------------------------

Swabs were obtained rectally (5 cm ab ano) (Transwab^®^ m40 compliant, mwe, Corsham, Wiltshire, UK) and subsequently streaked onto chromogenic selective agar (VRESelect^TM^, Biorad, München, Germany). Species identification of suspected colonies (pink or blue) was performed with MALDI-TOF MS (Bruker Corporation, Bremen, Germany). In accordance with the current European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards for clinical breakpoints \[[@B35-microorganisms-07-00400]\], susceptibility testing was performed using the VITEK^®^ 2 system (bioMérieux, Nürtingen, Germany). Confirmation of species identification and glycopeptide resistance (*vanA*, *vanB*, *vanC1*, and *vanC2/3*) was done using the GenoType *Enterococcus*^®^ line probe (Hain Lifescience, Nehren, Germany). In addition, the presence of *van* genes in the tested isolates was confirmed by the whole genome sequencing (WGS) data.

2.4. Whole Genome Sequence-Based Typing {#sec2dot4-microorganisms-07-00400}
---------------------------------------

To uncover genetic relationships of the VRE strains, isolates were compared via WGS-based typing using the Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA) \[[@B36-microorganisms-07-00400]\]. After quality trimming, coding core genome regions were compared in a gene-by-gene approach (core genome multilocus sequence typing, cgMLST) using the SeqSphere+ software version 6.0.0 (Ridom GmbH, Münster, Germany) and the published *E. faecium* cgMLST target scheme \[[@B37-microorganisms-07-00400]\]. To display the clonal relationship of genotypes, the minimum spanning tree algorithm was applied using the same software. Genotypes differing in ≤3 alleles were rated as closely related. For backwards compatibility with classical molecular typing (i.e., multilocus sequence typing (MLST)), the MLST sequence types (STs) were extracted from the WGS data in silico.

2.5. Statistical Analysis {#sec2dot5-microorganisms-07-00400}
-------------------------

All data were expressed as absolute numbers or percentages. Descriptive statistics were performed using the IBM SPSS Statistics software (Armonk, NY, USA). For risk factor analysis, chi-square or Fisher's exact test were used for categorical data as appropriate. Normally distributed continuous variables were compared using the two-sided Student's *t*-test. Statistical significance was set at *p* \< 0.05.

3. Results {#sec3-microorganisms-07-00400}
==========

3.1. VRE Persistence and Associated Risk Factors {#sec3dot1-microorganisms-07-00400}
------------------------------------------------

In total, 1059 VRE patients were admitted to the UHM. Of these, 134 had a pre-existing VRE medical history, while in the remaining 925 patients, VRE was newly detected. Follow-up results at least 10 weeks after initial detection of VRE colonization/infection were available for 463 patients. Of these, 202 (43.6%) patients were still VRE-positive, thus defining the status of VRE persistence, while VRE clearance was determined in the remaining 261 patients (56.4%). Clinical characteristics favoring VRE persistence are summarized in [Table 1](#microorganisms-07-00400-t001){ref-type="table"}. Long-term carriers were significantly older and suffered from hemato-oncological diseases. Moreover, they had more frequent and longer hospital stays and received antibiotic agents more often and for a longer time. The antibiotic substances piperacillin/tazobactam, ceftriaxone, clindamycin, trimethoprim/sulfamethoxazole, ciprofloxacin, and vancomycin were significantly associated with VRE persistence.

3.2. VRE Genotypes and Genetic Distribution of Strains {#sec3dot2-microorganisms-07-00400}
------------------------------------------------------

[Table 2](#microorganisms-07-00400-t002){ref-type="table"} shows the *van* genotypes in patients with VRE clearance and persistence in detail. Out of 463 patients, ca. 71% of all detected strains harbored *vanB*. Of all isolates derived from long-term and non-long-term carriers, 365 isolates were available for WGS. The following STs were detected among these samples: ST117 (60.8%; 222 isolates), ST262 (12.6%, 46), ST203 (11.5%, 42), ST80 (6.0%, 22), ST721 (4.9%; 18), ST78 (1.9%, 7), ST192 (0.8%; 3), and ST17 (0.5%; 2). Three isolates (0.8%) could not be correctly typed. cgMLST-based typing resulted in several clusters of genetically closely related genotypes ([Figure 1](#microorganisms-07-00400-f001){ref-type="fig"}). There was no specific clustering of isolates associated with VRE persistence or VRE clearance.

4. Discussion {#sec4-microorganisms-07-00400}
=============

VRE are a rising problem worldwide. While previous studies have analyzed the risk factors for VRE acquisition, we observed the temporal evolvement of VRE eventually leading to persistence or clearance.

By prospectively following patients with VRE detection at admission, we surprisingly found that 56.4% of patients spontaneously lost VRE 10 weeks after first detection. In contrast to other studies, which describe a rate of persistence of approximately 80% \[[@B38-microorganisms-07-00400],[@B39-microorganisms-07-00400]\], only 43.6% of our patients were identified as long-term carriers. *vanB*-positive strains were more common among both persistent carriers (70.3%) and patients with clearance (71.3%), concurring with the national trend in Germany \[[@B40-microorganisms-07-00400]\]. cgMLST analysis of the VRE strains revealed no specific genetic pattern that favors VRE persistence or clearance. Hence, host-associated factors and treatment strategies are very likely the main factors determining the VRE carrier status.

We found that factors strongly associated with VRE persistence are similar to those known to favor colonization, such as hemato-oncological diseases, long and multiple hospital stays, and steroid and antibiotic therapy \[[@B3-microorganisms-07-00400],[@B4-microorganisms-07-00400],[@B12-microorganisms-07-00400],[@B14-microorganisms-07-00400],[@B17-microorganisms-07-00400],[@B32-microorganisms-07-00400],[@B41-microorganisms-07-00400]\]. Dialysis, a further factor described to favor VRE colonization \[[@B32-microorganisms-07-00400],[@B33-microorganisms-07-00400]\], was not shown to be a risk factor for VRE carriage persistence in our study. Moreover, regiments using broad spectrum antibiotics like third generation cephalosporines increased the likelihood of VRE persistence, possibly due to a disruption of the normal gut flora, allowing the selective proliferation of VRE, as previously stated \[[@B42-microorganisms-07-00400]\]. Fortunately, this risk factor can be modified: the implementation of institutional policies for rational use of antibiotics, such as antibiotic stewardship programs, represent a valuable preventive strategy to tackle the VRE problem as reported in studies showing a significant reduction of colonization and infection with antibiotic-resistant bacteria as a direct result of such approaches \[[@B34-microorganisms-07-00400]\]. Moreover, the constant emergence of new bacterial resistance mechanisms calls for the development of new antimicrobial substances. Recent studies have described novel compounds that could be potentially employed in the treatment of infections with vancomycin-resistant enterococci \[[@B43-microorganisms-07-00400],[@B44-microorganisms-07-00400]\].

In contrast to MRSA, there are no eradication approaches for VRE. Therefore, infection control bundle strategies rely solely on screening and isolation of colonized patients. Since screening is cost-intensive \[[@B3-microorganisms-07-00400]\] and isolation of patients is associated with reduced quality of care \[[@B45-microorganisms-07-00400]\], a risk stratification upon admission of patients with history of VRE would allow to identify those likely to be cleared of colonization, thus not requiring them to be isolated. This would lead to a reduction of unnecessary contact precautions and costs for microbiological diagnostic procedures.

Our study has some limitations. First, our results do not reveal causality but correlations between certain risk factors and the persistence of VRE carriage. Second, we did not consider the patients' environment, which have also been suggested to influence the risk of VRE colonization \[[@B24-microorganisms-07-00400],[@B46-microorganisms-07-00400]\]. However, neither of these limitations hindered the achievement of the study's main objectives, namely, the determination of the VRE clearance rate and the identification of risk factors significantly associated with VRE persistence.

5. Conclusions {#sec5-microorganisms-07-00400}
==============

Infection control management of VRE positive patients is linked to increased use of human and financial resources. Only approximately every second VRE patient becomes a long-term carrier. Hence, the identification of patient-associated risk factors may be helpful in predicting the VRE carriage, allowing for infection control measures as screening and contact precautions to focus on patients at increased risk for VRE persistence.
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microorganisms-07-00400-t001_Table 1

###### 

Comparison of clinical characteristics of patients with vancomycin-resistant enterococci (VRE)-persistence and VRE-clearance, Münster University Hospital, 2016--2018.

  -------------------------------------------------------------------------------------------------------------
  Clinical Characteristic                         VRE-Persistence\         VRE-Clearance\           *p*-Value
                                                  (*n* = 202)              (*n* = 261)              
  ----------------------------------------------- ------------------------ ------------------------ -----------
  Sex (male)                                      57.4%                    60.5%                    0.50

  Age (years)                                     59.7 (range 1.8--93.1)   55.7 (range 0.6--97.7)   0.02

  Overall length of stay (days)                   76.4 (range: 1--478)     37.8 (range 1--216)      0.001

  Average length of stay per admission (days)     35.3 (1--340)            20.1 (1--188)            0.001

  Number of stays                                 3.3 (range: 1--29)       2.3 (range: 1--10)       0.001

  Hemato-oncological disease                      119 (58.9%)              122 (46.7%)              0.01

  Liver insufficiency                             41 (20.3%)               43 (16.5%)               0.29

  Liver transplantation                           9 (4.5%)                 22 (8.4%)                0.09

  Kidney insufficiency                            88 (43.6%)               114 (43.7%)              0.98

  Dialysis                                        37 (18.3%)               35 (13.4%)               0.15

  Immunosuppressive disease                       143 (70.8%)              169 (64.8%)              0.17

  Inflammatory bowel disease                      2 (1.0%)                 5 (1.9%)                 0.47

  Rheumatic disease                               1 (0.5%)                 5 (1.9%)                 0.24

  Granulomatosis with polyangiitis                1 (0.5%)                 1 (0.4%)                 1.00

  HIV                                             1 (0.5%)                 2 (0.8%)                 0.58

  Systemic lupus erythematosus                    1 (0.5%)                 1 (0.4%)                 1.00

  Idiopathic thrombocytic purpura                 0 (0.0%)                 1 (0.4%)                 1.00

  Transplantation                                 20 (10.0%)               39 (14.9%)               0.13

  Multiple sclerosis                              1 (0.5%)                 1 (0.4%)                 1.00

  Systemic scleroderma                            1 (0.5%)                 0 (0.0%)                 0.44

  Antibiotics                                     191 (94.6%)              222 (85.1%)              0.001

  Penicillin                                      9 (4.5%)                 8 (3.1%)                 0.46

  Ampicillin                                      12 (5.9%)                8 (3.1%)                 0.17

  Amoxicillin                                     5 (2.5%)                 6 (2.3%)                 1.00

  Ampicillin/sulbactam                            14 (6.9%)                20 (7.7%)                0.86

  Amoxicillin/clavulanic acid                     17 (8.4%)                16 (6.1%)                0.37

  Flucloxacillin                                  18 (8.9%)                18 (6.9%)                0.48

  Piperacillin/tazobactam                         145 (71.3%)              134 (51.3%)              \<0.001

  Cefuroxime                                      19 (9.4%)                24 (9.2%)                1.00

  Ceftriaxone                                     43 (21.3%)               36 (13.8%)               0.03

  Ciprofloxacin                                   109 (54.0%)              76 (29.1%)               \<0.001

  Erythromycin                                    9 (4.5%)                 10 (3.8%)                0.82

  Clindamycin                                     35 (17.3%)               21 (0.8%)                0.004

  Colistin                                        8 (4.0%)                 3 (0.1%)                 0.06

  Trimethoprim/sulfamethoxazole                   102 (50.5%)              88 (33.7%)               \<0.001

  Metronidazole                                   20 (9.9%)                18 (6.9%)                0.31

  Rifampicin                                      17 (8.4%)                18 (6.9%)                0.60

  Fosfomycin                                      10 (5.0%)                10 (3.8%)                0.65

  Vancomycin                                      92 (45.5%)               59 (22.6%)               \<0.001

  Duration of treatment with antibiotics (days)   97.7 (range: 0--430)     25.0 (range: 0--372)     \<0.001

  Systemic steroids                               121 (59.9%)              116 (44.4%)              0.001

  Admission from another hospital                 62 (30.7%)               60 (23%)                 0.06

  Admission from other ICUs                       2 (1.0%)                 9 (3.4%)                 0.09
  -------------------------------------------------------------------------------------------------------------
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###### 

Number of Vancomycin-resistant enterococci (VRE) patients and genotype distribution stratified by VRE persistence and VRE clearance, Münster University Hospital, 2016--2018.

  Colonization Status   No. of Patients with *Van* Genotype (%)                                       
  --------------------- ----------------------------------------- ------------- ---------- ---------- -------------
  **VRE-persistence**   58 (28.7%)                                142 (70.3%)   2 (1.0%)   0 (0.0%)   202 (43.6%)
  **VRE-clearance**     64 (24.5%)                                186 (71.3%)   2 (1.0%)   9 (3.4%)   261 (56.4%)
  **Total**             122 (26.3%)                               328 (70.8%)   4 (1.0%)   9 (1.9%)   463 (100%)

[^1]: Authors contributed equally.
